Akums Drugs & Pharmaceuticals Ltd
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
- Market Cap ₹ 13,091 Cr.
- Current Price ₹ 832
- High / Low ₹ 1,176 / 724
- Stock P/E
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 2.40 %
- ROE -3.57 %
- Face Value ₹ 2.00
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -6.60% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 1,464 | 1,651 | 2,723 | 3,672 | 3,655 | 4,178 | |
| 1,340 | 1,507 | 2,485 | 3,761 | 3,361 | 4,055 | |
| Operating Profit | 124 | 144 | 238 | -89 | 294 | 123 |
| OPM % | 8% | 9% | 9% | -2% | 8% | 3% |
| 6 | 6 | 11 | 7 | 15 | 8 | |
| Interest | 23 | 22 | 7 | 17 | 46 | 51 |
| Depreciation | 31 | 38 | 70 | 95 | 113 | 126 |
| Profit before tax | 77 | 89 | 172 | -193 | 150 | -45 |
| Tax % | 51% | 50% | 28% | 30% | 35% | -102% |
| 43 | 61 | 123 | -251 | 98 | 1 | |
| EPS in Rs | 366.55 | 523.23 | 943.49 | -35.30 | 6.63 | -0.28 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -120% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -7% |
| Last Year: | -4% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 14 | 29 | 29 |
| Reserves | 493 | 628 | 884 | 608 | 689 | 681 |
| 255 | 213 | 130 | 395 | 619 | 565 | |
| 293 | 318 | 1,137 | 2,033 | 1,905 | 2,229 | |
| Total Liabilities | 1,042 | 1,161 | 2,152 | 3,050 | 3,241 | 3,504 |
| 444 | 501 | 904 | 1,021 | 1,097 | 1,191 | |
| CWIP | 0 | 11 | 17 | 31 | 103 | 195 |
| Investments | 0 | 18 | 20 | 0 | 0 | 0 |
| 598 | 632 | 1,212 | 1,998 | 2,041 | 2,118 | |
| Total Assets | 1,042 | 1,161 | 2,152 | 3,050 | 3,241 | 3,504 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 72 | 89 | 131 | 32 | 177 | 498 | |
| -150 | -123 | -109 | -235 | -305 | -331 | |
| 66 | 37 | -91 | 236 | 125 | -108 | |
| Net Cash Flow | -11 | 4 | -70 | 33 | -4 | 59 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 68 | 57 | 71 | 88 | 84 | 73 |
| Inventory Days | 114 | 115 | 93 | 112 | 117 | 90 |
| Days Payable | 67 | 60 | 74 | 92 | 91 | 76 |
| Cash Conversion Cycle | 115 | 112 | 90 | 109 | 111 | 87 |
| Working Capital Days | 78 | 73 | 79 | 84 | 89 | 76 |
| ROCE % | 14% | -16% | 22% | 2% |
Documents
Announcements
-
Order Passed U/S 250 Of The Income Tax Act, 1961 In Favor Of The Company.
12 Sep - Order passed in favor of the company under Income Tax Act.
-
Grant Of Patent Certificate
12 Sep - Grant of patent for room stable Hydroxyurea oral suspension.
-
General Update
4 Sep - Akums appoints Shantanu R Chobhe as Corporate Quality Assurance Head.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
4 Sep - Transcript of Earnings / Analyst Conference Call held for limited reviewed un-audited financial results of Q1 FY25.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
30 Aug - Audio recording of Q1 FY25 earnings conference call.
Concalls
-
Sep 2024Transcript PPT REC
Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.